Abstract:Based on our hypothesis that epitope vaccine may be a new strategy to induce high levels of neutralization antibodies against HIV–1, we prepared multiple–epitope vaccines using three neutralizing epitopes (GPGRAFY, RILAVERYLKD and ELDKWA) of HIV–1 gp160, and characterized their immunogenicity. Peptide 1 [C–G–(ELDKWA–GPGRAFY)2–K] and peptide 2 (CG–GPGRAFY–ELDKWA–G–RILAVERYLKD) were synthesized and conjugated with carrier protein bovine serum albumin (BSA). After vaccination antibody responses to these immunogens were induced and evaluated by ELISA. The C–G–(ELDKWA–GPGRAFY)2–K–BSA (BSA: carrier protein) multiple–epitope vaccine induced a strong antibody response to the C–G–(ELDKWA–GPGRAFY)2–K peptide (antibody titer: 1:25,600) and C–(ELDKWAG)4 peptide (antibody titer: 1:12,800), but a weak antibody response to the C–(GPCGRAFY)4 peptide. The CG–GPGRAFY–ELDKWA–G–RILAVERYLKD–K–BSA (BSA: carrier protein) multiple–epitope vaccine also induced strong antibody response to the CG–GPGRAFY–ELDKWA–G–RILAVERYLKD–K peptide (antibody titer: 1:25,600) and C–(ELLDKWAG)4 peptide (antibody titer: 1:6,400), a very strong response to C–(RIVALVERYLKD–G)2–K peptide (dilution: 1:102,400), and a very weak response to the C–(GPGRAFY)4 peptide (dilution: 1:400) in mice. Both antisera induced by both multiple–epitope vaccines interacted with the recombinant soluble gp41 (rgp41), but did not bind two control peptides. In comparison with both epitope vaccines, the rgp160 subunit vaccine could induce weak epitope–specific antibody response to these three epitopes on the three epitope peptides and V3, N–domain and C–domain peptides (dilution: 1:400–1:1,600). These results indicate that both multiple–epitope vaccines could induce high levels of antibodies to both neutralizing epitopes RILAVERYLKD and ELDKWA, while the GPGRAFY epitope on both vaccines appeared to have weak immunogenicity. Both multiple–epitope vaccines showed significant potency on inducing high levels of epitope–specific neutralization antibodies in comparison with rgp160 subunit vaccine.

A study on loading multiple epitopes with a single peptide

Identification and Analysis of B Cell Epitopes of Hemagglutinin of H1N1 Influenza Virus.

Multi-epitope vaccines, from design to expression; an in silico approach

Multi-Epitope Vaccine Design Using an Immunoinformatic Approach for SARS-CoV-2

Using a Machine-Learning Approach to Predict Discontinuous Antibody-Specific B-Cell Epitopes

Design and construction of a recombinant epitope-peptide gene as a universal epitope-vaccine strategy.

Identification of a universal antigen epitope of influenza A virus using peptide microarray

Multiepitope Fusion Antigen: MEFA, an Epitope- and Structure-Based Vaccinology Platform for Multivalent Vaccine Development.

Epitope-directed monoclonal antibody production using a mixed antigen cocktail facilitates antibody characterization and validation

Multifaceted Characterization of Recombinant Protein-Based Vaccines: an Immunochemical Toolbox for Epitope-Specific Analyses of the Hepatitis E Vaccine.

H1N1 Influenza Virus Epitopes Classified by Monoclonal Antibodies.

Effects of vector fusion peptides on the conformation and immune reactivity of epitope-shuffled, recombinant multi-epitope antigens.

The Immunologic Dominance of an Epitope Within a Rationally Designed Poly-Epitope Vaccine is Influenced by Multiple Factors.

Recombinant Protein Comprising Multi-Neutralizing Epitopes Induced High Titer of Antibodies Against Influenza A Virus

Similarity between segments in protein conformational epitopes and MHC II peptides.

A Combination of Epitope Prediction and Molecular Docking Allows for Good Identification of MHC Class I Restricted T-cell Epitopes.

Predicting Immunogenic T-cell Epitopes by Combining Various Sequence-Derived Features.

Quantitative structure-activity relationship modeling of class Ⅰ MHC epitope based on structural properties of amino acid

Repeated Epitope In The Recombinant Epitope-Peptide Could Enhance Eldkwa-Epitope-Specific Antibody Response

Precise Assembly of Multiple Antigens on Nanoparticles with Specially Designed Affinity Peptides

Immunogenicity of Neutralizing Epitopes on Multiple–Epitope Vaccines Against HIV–1